Trial Profile
Phase III, Open, Multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC Compared to a Booster Dose of Infanrix Hexa When Given to 14 Month-old Subjects Primed in Study DTPa-HBV-IPV-097 & Boosted in Study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Oct 2023
Price :
$35
*
At a glance
- Drugs Hib-meningococcal vaccine group C conjugate (Primary) ; DTaP-hepatitis B-poliovirus vaccine; Hepatitis B vaccine recombinant; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa); Hib-DTaP-poliovirus vaccine; Meningococcal vaccine group C conjugate
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal group C infections; Pertussis; Poliomyelitis; Tetanus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK